GHK-Cu (cognitive angle)
Also known as: Gly-His-Lys-Cu · Copper tripeptide-1
A naturally occurring tripeptide-copper complex best known for skin and tissue-repair effects, but with a distinct cognitive-research literature covering gene-expression modulation, antioxidant defence, and indirect neurotrophic effects.
- Category
- Neurogenesis
- Half-life
- Short plasma half-life; gene-expression effects persist beyond clearance
- Formula
- C₁₄H₂₄N₆O₄Cu (as Cu complex)
- Weight
- 402.93 g/mol (Cu complex)
- Sequence
- Gly-His-Lys (with bound Cu²⁺)
Section 1
Overview
GHK-Cu is a naturally occurring tripeptide — glycine-histidine-lysine — that complexes copper ions in plasma and tissue. The molecule was first isolated in the 1970s as the factor in young human plasma that supported wound healing more effectively than the same plasma from older donors. Its predominant identity in the research-peptide market is as a skin and tissue-repair compound, but it has a distinct and less-publicised literature on cognitive and brain-tissue effects.
The cognitive case for GHK-Cu rests on three observations. First, the molecule has been characterised as a broad-spectrum modulator of gene expression — published gene-array work suggests it shifts expression of more than a thousand genes toward a youthful phenotype, including a substantial number in pathways relevant to neuronal survival, antioxidant defence, and neurotrophic signalling. Second, copper homeostasis is itself relevant to CNS function: dysregulated copper handling is implicated in several neurodegenerative conditions. Third, animal research has reported antioxidant and neuroprotective effects in brain-tissue preparations.
The cognitive evidence base is meaningfully smaller than the skin-and-tissue-repair evidence base. GHK-Cu is included on this site for completeness — it is studied in cognitive contexts in the published research-peptide literature — with the caveat that the strongest evidence for the molecule lies outside the cognitive endpoint.
Section 2
Discovery & History
- Isolated by Loren Pickart and colleagues in 1973 as the active factor in young human plasma that supported tissue repair.
- Initial characterisation focused on wound healing and tissue regeneration; cognitive and brain-tissue effects were investigated more sporadically thereafter.
- Widely adopted in cosmetic skin-care formulations from the 1990s onwards under regulatory frameworks distinct from the medicinal-product pathway.
- Cognitive and gene-expression research has continued in academic and independent contexts, generating the broader 'pleiotropic regulator' framing the molecule is now described under.
Section 3
Mechanism of Action
- 1Broad gene-expression modulation — published gene-array research reports shifts in expression of over 1,000 genes toward a youthful or pro-repair phenotype across multiple tissue types.
- 2Copper-dependent enzymatic effects — GHK-Cu delivers copper to tissues in a bioavailable form, supporting the function of copper-dependent enzymes including superoxide dismutase (antioxidant defence) and lysyl oxidase (extracellular matrix remodelling).
- 3Antioxidant effects via upregulation of endogenous antioxidant enzyme expression and direct radical-scavenging by the copper-peptide complex.
- 4Reported neuroprotective effects in animal models, attributed to combined antioxidant, anti-inflammatory, and possibly mild trophic mechanisms.
- 5Modulation of inflammatory gene expression, with reduction of pro-inflammatory markers in tissue-injury models.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Antioxidant and tissue-protective effects in brain-tissue preparations under oxidative challenge.
- 2Broad pro-repair gene-expression signature relevant to ageing-related cognitive decline contexts.
- 3Reported neuroprotective effects in animal models of CNS injury.
- 4Copper-delivery role supporting endogenous antioxidant enzyme function.
- 5Naturally occurring molecule with extensive non-cognitive safety record from cosmetic use, providing a partial safety floor.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration |
|---|---|---|---|
| Subcutaneous / intranasal (research) | Microgram to milligram range in animal protocols | Daily during a course | Variable across published protocols |
Note: Topical GHK-Cu (cosmetic preparations) is a separate product category; the cognitive-research material is distinct.
Section 6
Administration Routes
- Subcutaneous injection — primary route in animal research.
- Intranasal administration documented in some research protocols.
- Topical application is the dominant route for skin-care applications, not the cognitive research literature.
- Oral administration faces the standard peptide-degradation barrier.
Section 7
Safety Profile
Commonly reported
- · Generally well-tolerated in animal research and in the substantial cosmetic-use safety record
- · Mild local reactions at injection or topical-application site occasionally reported
Rare / theoretical
- · Copper toxicity is theoretically possible with excessive systemic administration; the standard research doses are far below relevant toxicity thresholds
- · The cognitive-research safety literature specifically is sparser than the general safety record
- · Long-term effects of chronic systemic GHK-Cu administration in cognitive contexts are uncharacterised
Contraindications
- · Not authorised for human medicinal use in the UK
- · Pregnancy and lactation — limited data
- · Wilson's disease and other copper-metabolism disorders — relative contraindication via the copper component
Section 8
UK & EU Regulatory Context
United Kingdom
Not licensed as a medicine in the UK. Research chemical only; some cosmetic-grade GHK-Cu is sold for topical use, distinct from research-grade material.
European Union
Not approved by the EMA as a medicine. Used in cosmetic formulations under separate regulatory framework.
Section 9
Clinical Studies Summary
GHK-Cu gene-expression effects in human fibroblast cultures
Microarray analysis demonstrating modulation of expression of over 1,000 genes following GHK-Cu exposure, with the modulation pattern aligning with a shift toward a younger transcriptional phenotype across antioxidant, repair, and growth-factor pathways.
Neuroprotective effects of GHK-Cu in cerebral ischaemia models
Animal-model work reporting reduced infarct volume and improved neurological scoring in rodents receiving GHK-Cu prior to or shortly after experimental cerebral ischaemia, attributed to combined antioxidant and anti-inflammatory mechanisms.
Antioxidant enzyme modulation by GHK-Cu in brain tissue
Upregulation of superoxide dismutase and catalase expression in brain tissue following GHK-Cu administration, supporting the antioxidant-defence pathway as one of the molecule's principal neuroprotective routes.
Section 10
Frequently Asked Questions
Section 11
Sourcing for Laboratory Research
Sourcing GHK-Cu (cognitive angle) for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain GHK-Cu (cognitive angle) from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: research peptides are sold strictly for in vitro and preclinical laboratory purposes. Importation or supply for human consumption is not permitted under UK medicines legislation.